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l Figure 3 shows the yearly treatment cost of patients over the time period. The total costs add up to € 27'612'238 in 2015 and the total treatment cost grew yearly on average by 11.8% from 2012 to 2015.
The total number of patients grew yearly on average by 9.7% from 2012-2015. As expected, the key cost driver were biological agents which account for 91.6% of total cost (in 2015) . The costs could be slightly overestimated due to potential intersections of patients who begin, repeat or switch the therapy. With regard to 2016, comprehensive data sets only exist for Q1/2016 and Q2/2016, data from Q3/2016 is incomplete. This has to be taken into account when interpreting the data. • The study demonstrated that the level of share of prescriptions of biological agents considered is low.
• Adalimumab and etanercept are administered mostly to patients who are already on treatment (in 2015 adalimumab 38.3 % vs. etanercept 31.3 %).
CONCLUSIONS:
l Adalimumab and etanercept are those biological agents mainly used by patients who are already on treatment.
l Costs grew steadily over the last four years with biological agents being the key cost driver.
l Total costs in 2015 were € 27.6 million and on average € 17'872 per patient.
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A CLAIMS DATA ANALYSIS OF BIOLOGICAL AGENTS FOR PSORIATIC ARTHRITIS IN GERMANY

METHODS:
l The design is a retrospective claims data analysis. l The study evaluated direct medical costs (drugs, outpatient care and hospital admission), hospital admission and change in medication.
l Treatment costs included costs for biological agents which were approved for the treatment of PSA (as of April 2017, see also Table  2 ). Furthermore, the following medication groups were considered to be PSA related (see also l In case that a patient changed therapy during the observation period, he was further included only if he continued receiving a biological agent.
l Figure 1 depicts an overview of the analysis of the sample. 
RESULTS:
l Most patients with PsA are aged above 46, thereby the proportion below 17 years' account for less than 1%. The average age of all age cohorts is 50.8 years, with the subgroup of men slightly younger than women (49.0 yr men vs. 52.7 yr women).
• The distribution of men and women is almost the same (49.9% male vs 50.1% female) (see also Figure 2 ). 
